



13w

# TRANSMITTAL FORM

(To be used for all correspondence  
after initial filing)


<b>TRANSMITTAL FORM</b> <i>(To be used for all correspondence after initial filing)</i>	Application Number	10/688,838
	Filing Date	October 17, 2003
	First Named Inventor	Jiangchun Xu
	Art Unit	1632
	Examiner Name	
	Attorney Docket No.	210121.427D4

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement; Form PTO-1449 (6 Sheets) <input type="checkbox"/> Cited References <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 <input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Request for Corrected Filing Receipt <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Declaration <input type="checkbox"/> Statement under 37 CFR 3.73(b) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Other Enclosure(s) (please identify below): <hr/> <hr/> <hr/> <hr/>
<u>Remarks</u>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name	Seed Intellectual Property Law Group PLLC	Customer Number <b>00500</b>
Signature		
Printed Name	William T. Christiansen, Ph.D.	
Date	November 22, 2004	Reg. No. 44,614

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.		
Signature		
Typed or printed name	Lawrence Teague	Date: November 22, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. 1533883



PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

November 22, 2004

Lawrence Teague

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Jiangchun Xu et al.  
Application No. : 10/688,838  
Filed : October 17, 2003  
For : COMPOUNDS FOR IMMUNOTHERAPY OF PROSTATE  
CANCER AND METHODS FOR THEIR USE

Art Unit : 1632  
Docket No. : 210121.427D4  
Date : November 22, 2004

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449. This application is a divisional and relies, under 35 U.S.C. § 120, on the earlier filing date of prior application USAN 09/115,453, filed July 14, 1998, now U.S. Patent 6,657,056; which is a continuation-in-part of USAN 09/030,607, filed February 25, 1998; which is a continuation-in-part of USAN 09/020,956, filed February 9, 1998; which is a continuation-in-part of USAN 08/904,804, filed August 1, 1997; which is a continuation-in-part of USAN 08/806,099, filed February 25, 1997. The references listed on the attached Forms PTO-1449 were submitted to and/or cited by the Office in these prior applications and, therefore, are

not required to be provided in the present application. If the Examiner wishes, copies will be provided upon request.

As to any reference made of record on the attached Form PTO-1449, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,  
Seed Intellectual Property Law Group PLLC

---

William T. Christiansen, Ph.D.  
Registration No. 44,614

JEH:ljt

Enclosures:

Postcard  
Transmittal Form  
Form PTO-1449 (6 Sheets)

701 Fifth Avenue, Suite 6300  
Seattle, Washington 98104-7092  
Phone: (206) 622-4900  
Fax: (206) 682-6031

1533886

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.427d4	APPLICATION NO. 10/688,838
INFORMATION DISCLOSURE STATEMENT (If necessary, attach several sheets if necessary)		APPLICANTS Jiangchun Xu et al.			
		FILING DATE October 17, 2003		GROUP ART UNIT 1632	

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,786,148	07/28/98	Bandman et al.	435	6	
	AB	6,130,043	10/10/00	Billing-Medel et al	435	6	
	AC	6,252,047	06/26/01	Billing-Medel et al.	530	350	
	AD	6,261,562	07/17/01	Xu et al.	424	185.1	
	AE	6,262,245	07/17/01	Xu et al.	536	23.5	
	AF	2002/0086301 A1	07/04/02	Billing-Medel et al.	435	6	
	AG						
	AH						
	AI						
	AJ						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AK	DE 19649207	11/27/96	Germany		X
	AL	EP 317 141 A2	05/24/89	EPO		
	AM	EP 652 014 A1	05/10/95	EPO		
	AN	EP 936 270 A2	08/18/99	EPO		X
	AO	WO 93/14755	08/05/93	PCT		

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AP		Ahn and Kunkel, "The structural and functional diversity of dystrophin," <i>Nature Genetics</i> 3: 283-291, April, 1993.
AQ		Alexeyev et al., "Improved antibiotic-resistance gene cassettes and omega elements for <i>Escherichia coli</i> vector construction and in vitro deletion/insertion mutagenesis," <i>Gene</i> 160: 63-67, 1995.
AR		Anderson, W.F. <i>Nature</i> 392:25-30, April 1998.

EXAMINER	DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.427d4	APPLICATION NO. 10/688,838
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		APPLICANTS		Jiangchun Xu et al.	
		FILING DATE October 17, 2003		GROUP ART UNIT 1632	

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	BB	WO 93/25224	12/23/93	PCT		
	BC	WO 94/09820	05/11/94	PCT		
	BD	WO 95/04548	02/16/95	PCT		
	BE	WO 95/14772	06/01/95	PCT (Cover page with English abstract only)		X
	BF	WO 95/30758	11/16/95	PCT		
	BG	WO 96/21671	07/18/96	PCT		
	BH	WO 97/33909	09/18/97	PCT		
	BI	WO 98/12302	03/26/98	PCT		
	BJ	WO 98/17687	04/30/98	PCT		
	BK	WO 98/20117	05/14/98	PCT		

**OTHER ART** (Including Author, Title, Date, Pertinent Pages, Etc.)

BL		Blok et al., "Isolation of cDNAs That Are Differentially Expressed Between Androgen-Dependent and Androgen-Independent Prostate Carcinoma Cells Using Differential Display PCR," <i>The Prostate</i> 26: 213-224, 1995.
BM		Bowie et al., <i>Science</i> 257:1306-10, March 1990.
BN		Chu et al., "CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity," <i>J. Exp. Med.</i> 186(10): 1623-1631, November 17, 1997.
BO		Coleman et al., <i>Fundamental Immunology</i> , Wm. C. Brown Publishers, Dubuque, Iowa, 1989, pp. 465-466.
BP		Database EMBL Accession No. AA453562, June 11, 1997, Hillier et al., "Homo Sapiens cDNA Clone 788180."

EXAMINER	DATE CONSIDERED
----------	-----------------

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.427d4	APPLICATION NO. 10/688,838
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		APPLICANTS Jiangchun Xu et al.			
		FILING DATE October 17, 2003	GROUP ART UNIT 1632		

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CA						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	CB	WO 98/31799	07/23/98	PCT		
	CC	WO 98/37093	08/27/98	PCT		
	CD	WO 98/37418	08/27/98	PCT		
	CE	WO 98/38310	09/03/98	PCT		
	CF	WO 98/39446	09/11/98	PCT		
	CG	WO 98/45435	10/15/98	PCT		
	CH	WO 98/50567	11/12/98	PCT		
	CI	WO 99/06548	02/11/99	PCT		
	CJ	WO 99/06550	02/11/99	PCT		
	CK	WO 99/06552	02/11/99	PCT		

**OTHER ART** (*Including Author, Title, Date, Pertinent Pages, Etc.*)

CL		Derwent Geneseq Database, Accession No. V58522, December 8, 1998.
CM		Derwent Geneseq Database, Accession No. V61287, January 6, 1999.
CN		Duerst and Nees, "Nucleic acid characteristic of late or early passage cells immortalized by papilloma virus-and related polypeptide(s) and antibodies, used for diagnosis and treatment of cervical cancer and assessing potential for progression of cervical lesions," Derwent World Patent Index, Accession No. 1998-121623, 1998. See also German Patent DE 19649207 C1.
CO		El-Shirbiny, "Prostatic Specific Antigen, <i>Advances In Clinical Chemistry</i> 31: 99-133, 1994.
CP		Ezzell, C., "Cancer vaccines: an idea whose time has come?" <i>The Journal of NIH Research</i> 7:46-49, January, 1995.

EXAMINER	DATE CONSIDERED
----------	-----------------

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.427d4	APPLICATION NO. 10/688,838
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		APPLICANTS		GROUP ART UNIT	
		Jiangchun Xu et al.		1632	
<b>U.S. PATENT DOCUMENTS</b>					

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	DA						

#### **FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	DB	WO 99/25825	05/27/99	PCT		
	DC	WO 99/31236	06/24/99	PCT		
	DD	WO 00/04149	01/27/00	WIPO		
	DE	WO 01/25272	04/12/01	WIPO		
	DF	WO 01/34802	05/17/01	WIPO		
	DG					

#### **OTHER ART** (Including Author, Title, Date, Pertinent Pages, Etc.)

DH		Gao et.al., "Blinded Evaluation of Reverse Transcriptase-Polymerase Chain Reaction Prostate-Specific Antigen Peripheral Blood Assay For Molecular Stging of Prostate Cancer," <i>Urology</i> 53(4): 714-721, 1999
DI		GenBank Accession Number AF047020, February 1, 1999.
DJ		Hara et al., "Characterization of cell phenotype by a novel cDNA library subtraction system: expression of CD8α in a mast cell-derived interleukin-4-dependent cell line," <i>Blood</i> 84(1):189-199, July 1, 1994.
DK		Harris et al., "Polycystic Kidney Disease 1: identification and analysis of the primary defect," <i>J. Am. Soc. of Nephrol.</i> 6:1125-1133, 1995.
DL		Hillier et al., Genbank Accession No. AA100799, December 23, 1997.
DM		Hillier et al., Genbank Accession No. R20590, April 18, 1995.
DN		Hudson, T., Genbank Accession No. G22461, May 31, 1996.

EXAMINER	DATE CONSIDERED
----------	-----------------

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.427d4	APPLICATION NO. 10/688,838
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		APPLICANTS		Jiangchun Xu et al.	
		FILING DATE October 17, 2003		GROUP ART UNIT 1632	

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	EA						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION
					YES      NO
	EB				

**OTHER ART** (Including Author, Title, Date, Pertinent Pages, Etc.)

	EC	Kroger, B. "New serine protease form human prostate, useful for identifying specific inhibitors, antibodies and probes," Derwent World Patent Index, Accession No. 99-432218, 1999. See also European Patent EP 936 270 A2.
	ED	National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA551449, September 5, 1997.
	EE	National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA551759, August 11, 1997.
	EF	National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA631143, October 31, 1997.
	EG	National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA653016, November 25, 1997.
	EH	NCBI Blast Search. SEQ ID NO:10 agaist GenBank+EMBL+DDBJ+PDB sequences, but no EST, STS, GSS, or phase 0,1 or 2 HTGS sequences. April 7, 2003.
	EI	NCBI Blast Search. SEQ ID NO:10 agaist GenBank+EMBL+DDBJ+PDB sequences from EST Divisions. February 19, 2003.
	EJ	NCBI Blast Search. SEQ ID NO:11 agaist GenBank+EMBL+DDBJ+PDB sequences, but no EST, STS, GSS, or phase 0,1 or 2 HTGS sequences. April 7, 2003.
	EK	NCBI Blast Search. SEQ ID NO:11 agaist GenBank+EMBL+DDBJ+PDB sequences from EST Divisions. April 7, 2003.
	EL	Nelson et al., Genbank Accession No. NP_004908, March 18, 2000.

EXAMINER	DATE CONSIDERED
----------	-----------------

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 210121.427d4	APPLICATION NO. 10/688,838
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Jiangchun Xu et al.	
		FILING DATE October 17, 2003	GROUP ART UNIT 1632

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	FA						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION
					YES NO
	FB				

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

FC	Robson et al., "Identification of prostatic androgen regulated genes using the differential display technique," <i>Proceedings Of The American Association For Cancer Research Meeting 86</i> , 36: p. 266, Abstract No. 1589, 1995.
FD	Schmidt-Wolf et al., "Activated T cells and cytokine-induced CD3 <sup>+</sup> CD56 <sup>+</sup> killer cells," <i>Annals of Hematology</i> 74:51-56, 1997.
FE	Sherman et al., "Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8," <i>Science</i> 258(5083):815-818, October 30, 1992.
FF	Short et al., "λ ZAP: a bacteriophage λ expression vector with <i>in vivo</i> excision properties," <i>Nucleic Acids Research</i> 16(15): 7583-7600, 1988.
FG	Sjögren, H., "Therapeutic Immunization Against Cancer Antigens Using Genetically Engineered Cells," <i>Immunotechnology</i> 3: 161-172, 1997.
FH	Stedman's Medical Dictionary--definition of vaccine, four pages, 1995.
FI	Theobald, et al., "Targeting p53 as a general tumor antigen," <i>Proc. Natl. Sci. USA</i> 92(25):11993-11997, December 5, 1995.
FJ	Vasmatzis et al., "Discovery of three genes specifically expressed in human prostate by expressed sequence tag database analysis," <i>Proc. Natl. Acad. Sci. USA</i> 95(1):300-304, January 6, 1998.
FK	Verma et al., <i>Nature</i> 389:239-242, September 1997.
FL	Zitvogel et al., "Eradication of Established Murine Tumors Using a Novel Cell-Free Vaccine: Dendritic Cell-Derived Exosomes," <i>Nature Medicine</i> 4(5): 594-600, May, 1998.

EXAMINER	DATE CONSIDERED
----------	-----------------

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).